ERCC2 and prostate cancer: Moreover, Chen et al. [113], Feng et al. [12], and Ma et al. [114] suggested that the ERCC2 Asp312Asn polymorphism contributed to the risk of non-Hodgkin lymphoma, lung cancer, and prostate cancer, respectively.